Aware Super Pty Ltd as trustee of Aware Super Invests $2.14 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Aware Super Pty Ltd as trustee of Aware Super purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 15,670 shares of the company’s stock, valued at approximately $2,139,000.

Other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in shares of Neurocrine Biosciences during the 4th quarter worth approximately $115,193,000. Wellington Management Group LLP boosted its position in Neurocrine Biosciences by 102.9% during the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock worth $198,939,000 after acquiring an additional 739,199 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Neurocrine Biosciences by 2,759.4% during the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company’s stock worth $100,705,000 after purchasing an additional 711,970 shares during the last quarter. Jennison Associates LLC grew its holdings in Neurocrine Biosciences by 145.1% in the 4th quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock valued at $112,025,000 after buying an additional 485,894 shares during the period. Finally, Norges Bank purchased a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $44,403,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft began coverage on Neurocrine Biosciences in a research report on Tuesday, February 11th. They set a “hold” rating and a $138.00 price target for the company. Guggenheim lowered their price target on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a report on Monday, February 10th. Wedbush dropped their price objective on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Bank of America dropped their target price on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Wednesday, March 26th. Three investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $161.86.

Insider Activity

In other news, insider Ingrid Delaet sold 623 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $149.29, for a total transaction of $93,007.67. Following the sale, the insider now owns 3,442 shares in the company, valued at $513,856.18. The trade was a 15.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kevin Charles Gorman sold 5,844 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total value of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares of the company’s stock, valued at $60,867,604.42. The trade was a 1.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 167,906 shares of company stock worth $24,671,530. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Up 1.3 %

Shares of NASDAQ:NBIX opened at $96.16 on Wednesday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.98. The firm has a market cap of $9.51 billion, a P/E ratio of 29.23, a P/E/G ratio of 0.77 and a beta of 0.33. The company has a 50 day moving average of $109.46 and a 200-day moving average of $122.74.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences announced that its Board of Directors has initiated a stock buyback program on Friday, February 21st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its shares are undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.